Topics

Glioblastoma | Treatment | Targeted therapy | RO7428731
Drug Type: Bispecific T-cell Engager (BiTE) - Target: CD3 x EGFRvIII - Action: stimulants, antagonists
Mechanism: CD3 stimulants(T cell surface glycoprotein CD3 stimulants), EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists)

Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > RO7428731

Whittle JR, Vieito M, Rohrberg K, Rodriguez-Ruiz ME, Castanon E, Mellinghoff IK, Van Linde M, Cloughesy T, Reardon DA, Chong RA, Rosenthal M, Wick A, Waldhauer I, Henkel N, Romagnoli B, Wolowski V, Dey S, Heil F, Heichinger C, Flinn N, Gou JP, Smith L, Prince F, Derks M, Roller A, Schiff C, Schneider M, Mason W.
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.
Neurooncol Adv. 2025 Jul 18;7(1):vdaf160. doi: 10.1093/noajnl/vdaf160. PMID: 40842640. Interventional study. ˍ ClinicalTrials.gov ID: NCT05187624.